The DOI matches its Crossref record; 217 of the 219 references it cites were found in a registry or an index.
Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics
Open accessAbstract
Central nervous system (CNS) disorders (e.g., multiple sclerosis, Alzheimer's disease, etc.) represent a growing public health issue, primarily due to the increased life expectancy and the aging population. The treatment of such disorders is notably elaborate and requires the delivery of therapeutics to the brain in appropriate amounts to elicit a pharmacological response. However, despite the major advances both in neuroscience and drug delivery research, the administration of drugs to the CNS still remains elusive. It is commonly accepted that effectiveness-related issues arise due to the inability of parenterally administered macromolecules to cross the Blood-Brain Barrier (BBB) in order to access the CNS, thus impeding their successful delivery to brain tissues. As a result, the direct Nose-to-Brain delivery has emerged as a powerful strategy to circumvent the BBB and deliver drugs to the brain. The present review article attempts to highlight the different experimental and computational approaches pursued so far to attain and enhance the direct delivery of therapeutic agents to the brain and shed some light on the underlying mechanisms involved in the pathogenesis and treatment of neurological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These drug administration pathways are characterized by many advantages such as increased patient compliance, high safety, remarkable ease of administration and rapid onset of action, as well as minimized systemic exposure [7].”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The human olfactory region, where olfactory and trigeminal nerve terminations are present, occupies 2–12.5 cm2, representing approximately 1.25–10% of the total surface area of the nasal cavity, and it is about 60 μm thick [7].”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 3,037
Zhou, H., Rivas, G., & Minton, A. P. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125817 · Cited by 2,160
Nanoemulsions versus microemulsions: terminology, differences, and similarities
McClements, D. J. (2011) · Soft Matter · doi:10.1039/c2sm06903b · Cited by 1,786
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,494
Cone, R. A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.008 · Cited by 1,459
Abuchowski, A., Es, T. V., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review
Fredenberg, S., Wahlgren, M., Reslow, M., & Axelsson, A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.049 · Cited by 1,293
Abuchowski, A., McCoy, J. R., Palczuk, N. C., Es, T. V., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,276
Nanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,256
Research works printed but not linked: 5
- M. Dahlin, Nasal administration of compounds active in the Central Nervous System - Exploring the olfactory pathway, Uppsala University, Ph.D Dissertation, (2000).
- V. Dhamankar, Cytochrome P450-mediated drug metabolizing activity in the nasal mucosa, The University of Iowa, Ph.D Dissertation, 2013.
- Pardeshi, 2015, Novel nasal devices for the efficient drug delivery: A systemic review, Indian J. Nov. Drug Deliv., 7, 1
- A. Mistry, The development and application of biological models for evaluation of direct nose-to-brain drug delivery systems. Ph.D Dissertation, University of Nottingham, (2009).
- K. Inthavong, K. Zhang, J. Tu, Modelling submicron and micron particle deposition in a human nasal cavity, Seventh International Conference on CFD in the Minerals and Process Industries, CSIRO, Melbourne, Australia, 2009.
Cited by
Sorted by citations
Gänger, S., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030116 · Cited by 447
Wu, I. Y., Bala, S., Škalko-Basnet, N., & di Cagno, M. P. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105026 · Cited by 439
Drug delivery to the central nervous system
Nance, E. A., Pun, S. H., Saigal, R., & Sellers, D. L. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00394-w · Cited by 442
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
Costa, C. P., Moreira, J. N., Lobo, J. M. S., & Silva, A. C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.012 · Cited by 317
Metadata
- Authors
- Bourganis, V., Kammona, O., Alexopoulos, A., & Kiparissides, C.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Centre for Research and Technology Hellas (GR)
- Corresponding author
- Kiparissides, Costas
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 128
- Pages
- 337-362
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W2801808920
- Cited by
- 357
- References
- 219
- Citations by year
- 2026: 31 · 2025: 39 · 2024: 52 · 2023: 61 · 2022: 53 · 2021: 54 · 2020: 38 · 2019: 23 · 2018: 6
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Pharmaceutics and Biopharmaceutics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- European Framework Programme for Research and Innovation Horizon 2020 (721098)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- nose-to-brain delivery, blood-brain barrier, brain drug delivery, central nervous system disorders, multiple sclerosis, Alzheimer's disease, intranasal drug delivery
- MeSH terms
- Administration, Intranasal, Animals, Biological Transport, Blood-Brain Barrier, Brain, Central Nervous System Agents, Central Nervous System Diseases, Drug Carriers, Epithelium, Humans, Nasal Mucosa, Permeability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
